Neuralab is building predictive neuromodulation.
We build AI that predicts how a patient's brain circuit will respond to stimulation, before the first pulse. Our first application is deep brain stimulation for Parkinson's disease.
Neuroscience has spent two decades mapping how the brain is wired. Diffusion MRI traces the large fibre bundles between regions in living people.1 Electron microscopy has mapped about 150 million synapses in a single cubic millimetre of human cortex.2 Cell atlases list the types of neurons in each region.3 These maps are extraordinary, and on their own they still do not tell you what a circuit will do.
A wiring diagram is static. The same connections can produce very different activity depending on neuromodulators, cell state, medication and disease.4 Human connectomes from imaging are coarse and are usually averaged across many people,5 and synapse-level maps come from small pieces of tissue that will never be stimulated.2 When a stimulating lead sits in a patient's subthalamic nucleus, the map can say which pathways run nearby. It cannot say how this patient's circuit will respond to 2 milliamps at 130 hertz.
That is the problem we work on. We use the connectome as a scaffold and build, patient by patient, a circuit model of how activity moves through it when it is perturbed. A circuit model is only useful if it predicts what happens next, so prediction is how we build it and how we judge it.
The data to do this has only recently started to exist. Sensing-enabled stimulators now record local field potentials from the same leads they stimulate through.6 Every change of setting is a perturbation with a recorded response, in a living human brain, repeated in every implanted patient. Very little of it is used today.
Each prediction can be checked. The model proposes a setting, the device records how the circuit responds, and the next prediction starts from a better model of that patient.
Why predict, and why now
The brain has started reporting back.
In 2025 the FDA approved the first adaptive deep brain stimulation system, which records from the same leads it stimulates through.6,7 For the first time, stimulation of a human circuit can come with a recorded response, day and night.
Reacting is not the same as choosing.
Today's closed-loop devices follow a single signal and turn stimulation up or down when it crosses a line.6 A device that can predict how the circuit will respond can choose where, how and when to stimulate, before the patient feels the consequences of a wrong guess.
The options have outgrown trial and error.
Directional leads, new waveforms and new targets have multiplied the settings a clinician could try,8 while each adjustment is still tried by hand, one clinic visit at a time.9 A search that large needs a model to narrow it before anyone is stimulated.
The models are finally ready.
Methods that learn from incomplete, multi-track records, which already work on proteins and language,10 can now be trained on patients whose data is never complete. Prediction is how those models are tested: they either forecast the response or they do not.
This is a long project with many unknowns. If you work on machine learning for neural data, run a DBS program, build stimulation hardware, or want to spend years on this problem, get in touch.
Research
All work →Sources
- Jbabdi S, Johansen-Berg H. Tractography: where do we go from here? Brain Connectivity 1(3), 2011. link
- Shapson-Coe A, et al. A petavoxel fragment of human cerebral cortex reconstructed at nanoscale resolution. Science 384, 2024. link
- Siletti K, et al. Transcriptomic diversity of cell types across the adult human brain. Science 382, 2023. Yao Z, et al. A high-resolution transcriptomic and spatial atlas of cell types in the whole mouse brain. Nature 624, 2023. link 1 link 2
- Bargmann CI, Marder E. From the connectome to brain function. Nature Methods 10, 2013. Marder E. Neuromodulation of neuronal circuits: back to the future. Neuron 76, 2012. link 1 link 2
- Horn A, et al. Connectivity predicts deep brain stimulation outcome in Parkinson disease. Annals of Neurology 82, 2017 (normative, group-average connectome). link
- Medtronic. Medtronic earns U.S. FDA approval for the world's first adaptive deep brain stimulation system for people with Parkinson's. Press release, 24 February 2025. link
- American Journal of Managed Care. Adaptive deep brain stimulation technology receives FDA approval for Parkinson disease. 26 February 2025. link
- Programming directional deep brain stimulation in Parkinson's disease. Stereotactic and Functional Neurosurgery 99(6), 2021. See also: Deep brain stimulation in movement disorders: recent advances and future directions. Practical Neurology, 2023. link 1 link 2
- University of Florida Fixel Institute. Impact of image-guided programming on initial DBS clinic visit times and outcomes. Abstract, 2023. link
- Devlin J, et al. BERT: pre-training of deep bidirectional transformers for language understanding. arXiv:1810.04805, 2018. Lin Z, et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science 379, 2023. link 1 link 2
Research
Our model, our first application and how we will test it. Each publication will carry the strongest evidence behind it: Conceptual, In silico, Retrospective or Prospective.
Kyklos
in developmentPredicts how a Parkinson's patient's basal ganglia circuit will respond to a deep brain stimulation setting, before it is applied.
Kyklos represents each patient as a record with parallel tracks: where the lead sits, what it connects to, what the circuit is doing, how the patient is doing and what medication they are on. No patient has every track filled in. The model is trained by hiding parts of these records and learning to restore them. You give it what is known about a patient, and it fills in the rest, with uncertainty on every value it supplies.
The same model can then be asked a direct question: given this patient, which perturbation is most likely to move their circuit toward a healthier state, and how sure are we? A circuit prior built from what is known about the basal ganglia and its loops ties the tracks together, so an answer comes with a reason as well as a prediction.
- Lead locationimaging
- Connectivitytractography
- RecordingsLFP from the device
- Symptomsscores, wearables
- Medicationdose and timing
predicts the circuit's response to each setting
- Contactwhere
- AmplitudemA or V
- FrequencyHz
- Pulse widthµs
- Adaptive rulewhen to go up or down
We will publish a model card for Kyklos with its tracks, its training objective, an open benchmark and its failure cases.
First application: Parkinson's disease
Deep brain stimulation works, and it is still programmed largely by hand.2,3 A clinician picks a contact, an amplitude, a frequency and a pulse width, watches the patient, adjusts, and asks them to come back in a few weeks. Finding good settings can take many visits, and each change waits for the next one.
A setting proposed by Kyklos is something anyone can check. It runs on the same approved device in any clinic, and its effect shows up in symptom scores, side effects, battery use and the number of programming visits.
The largest DBS population,4 the best-understood circuit, and a recorded biomarker already in clinical use.1
A well-defined circuit and a symptom that can be measured continuously.
Indications where data are scarce and circuit knowledge matters most, and where noninvasive methods such as TMS and focused ultrasound follow the same logic.
How we will test it
- In silico. From the data available at a patient's first programming visit, predict the settings their clinician eventually chose and how they responded. This starts on published cohorts and open datasets, against imaging-only and single-biomarker baselines.
- Prospective pilot. Compare model-proposed starting settings with standard programming in patients who already have sensing devices. Measure visits needed and symptom scores.
- Closed loop. Propose adaptive rules that use more of the recorded signal than a single frequency band, and test them on devices already in use.
We have not run these studies yet. We will publish what we find, including where the model does worse than a clinician. In the clinic, Neuralab begins as decision-support software, and a system that changes settings on its own is a regulated medical device that we will treat as one.5
Publications
Sources
- Medtronic. Medtronic earns U.S. FDA approval for the world's first adaptive deep brain stimulation system for people with Parkinson's. Press release, 24 February 2025. link
- University of Florida Fixel Institute. Impact of image-guided programming on initial DBS clinic visit times and outcomes. Abstract, 2023. link
- Cole ER, Miocinovic S. Are we ready for automated deep brain stimulation programming? Parkinsonism & Related Disorders, 2025. link
- Lozano AM, et al. Deep brain stimulation: current challenges and future directions. Nature Reviews Neurology 15, 2019. link
- U.S. Food and Drug Administration. Clinical Decision Support Software: guidance for industry and FDA staff. September 2022. link
Join us
There are no open roles yet. If this is the kind of problem you want to spend years on, write to us and tell us what you would do here.